Table 6.
CTC detection rates by oHSV1‐hTERT‐GFP method in lung cancer patients
| Type | Stage | Total number of patients | Number of patients with ≥ 4 CTCs | Median CTCs (range) | Mean CTCs | Sensitivity |
|---|---|---|---|---|---|---|
| Adenocarcinoma | I/II | 27 | 22 | 6 (1–37) | 7.81 | 0.815 |
| IIIa | 10 | 7 | 6 (0–12) | 5.90 | 0.700 | |
| IIIb | 8 | 5 | 6.5 (1–28) | 10.13 | 0.625 | |
| IV | 122 | 91 | 8 (0–81) | 10.98 | 0.664 | |
| Total | 167 | 125 | 8 (0–81) | 10.12 | 0.689 | |
| Squamous cell carcinoma | I/II | 8 | 8 | 14 (8–26) | 14.63 | 1.000 |
| IIIa | 8 | 7 | 6.5 (1–22) | 9.25 | 0.825 | |
| IIIb | 4 | 4 | 23.5 (5–43) | 23.75 | 1.000 | |
| IV | 10 | 5 | 3.5 (0–25) | 5.8 | 0.400 | |
| Total | 30 | 24 | 8.5 (0–43) | 11.47 | 0.767 | |
| Small cell lung cancer | LD | 18 | 13 | 4.5 (1–26) | 6.78 | 0.722 |
| ED | 20 | 16 | 6 (0–28) | 9.35 | 0.800 | |
| Total | 38 | 29 | 5 (0–28) | 8.13 | 0.763 | |
| Other NSCLCs | IIIa | 1 | 1 | / | / | 1.000 |
| IV | 4 | 4 | / | / | 1.000 | |
| Total | 5 | 5 | / | / | 1.000 | |
| Smoking | No | 127 | 95 | 7 (0–81) | 8.89 | 0.748 |
| < 400/year | 22 | 18 | 7.5 (1–54) | 12.27 | 0.818 | |
| ≥ 400/year | 91 | 70 | 9 (0–59) | 11.05 | 0.769 | |
| Total | 240 | 183 | 7 (0–81) | 10.02 | 0.7625 |
CTC, circulating tumor cells; ED, extensive disease; LD, limited disease; NSCLCs, non‐small cell lung cancers.